您现在的位置: 首页> 研究主题> 免疫脂质体

免疫脂质体

免疫脂质体的相关文献在1989年到2022年内共计120篇,主要集中在药学、肿瘤学、基础医学 等领域,其中期刊论文83篇、会议论文1篇、专利文献49227篇;相关期刊66种,包括聊城大学学报(自然科学版)、生物化学与生物物理学报:英文版、生物物理学报等; 相关会议1种,包括第19届全国儿科药学学术会议等;免疫脂质体的相关文献由334位作者贡献,包括杨曌、李利、胡兰荣等。

免疫脂质体—发文量

期刊论文>

论文:83 占比:0.17%

会议论文>

论文:1 占比:0.00%

专利文献>

论文:49227 占比:99.83%

总计:49311篇

免疫脂质体—发文趋势图

免疫脂质体

-研究学者

  • 杨曌
  • 李利
  • 胡兰荣
  • 郭广柱
  • 吴学玲
  • 崔社怀
  • 张颖
  • 徐梁
  • 李涛
  • 杨雪梅

免疫脂质体

-相关会议

  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

    • 崔潇; 马亚平; 张亚柯; 李英; 张芳霞; 王瑞
    • 摘要: 目的 将靶向HER2过表达细胞的HER2抗体偶联在纳米脂质体上,探索抗体偶联脂质体的方法.方法 通过乙醇注入法制备脂质体,表面修饰HER2抗体,成功制备Anti-HER2免疫脂质体;由SDS-PAGE电泳检测抗体偶联脂质体的连接效率;通过MTT检测免疫脂质体对乳腺癌细胞的细胞毒性;采用共聚焦显微镜和流式细胞技术检测免疫脂质体对乳腺癌细胞的靶向特异性.结果 粒径分析表明制备的空白脂质体与Anti-HER2免疫脂质体粒径均在100-135 nm之间;SDS-PAGE电泳显示HER2抗体与脂质体的连接效率为40%左右;MTT检测表明制备的免疫脂质体具有低细胞毒性;共聚焦显微镜和流式细胞仪检测结果均显示,Anti-HER2免疫脂质体对HER2阳性细胞具有明显的靶向特异性.结论 通过两种聚乙二醇连接方法成功制备了Anti-HER2免疫脂质体,数据表明DSPE-PEG2000-NHS(二硬脂酰磷脂酰乙酰胺-聚乙二醇2000-N-羟基丁二酰亚胺)连接方式效率更高.
    • 赵咏梅; 王瑞; 李新宇; 贺志高; 桂俊豪; 张东辉; 王晓燕; 张峰; 张羽
    • 摘要: 目的 探讨ANGPTL4免疫脂质体对转染脂多糖(lipopolysaccharide,LpS)诱发的急性肺损伤(acute lung injury,ALI)小鼠,肺损伤的影响.方法 采用逆相蒸发法制备ANGPTL4基因表达质粒与抗CD31抗体偶联的免疫脂质体;LPS诱发急性肺损伤小鼠模型;观察经ANGPTL4免疫脂质体转染的急性肺损伤小鼠的肺部炎症因子肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(interleukin-6,IL-6)水平和中性粒细胞活化标志物髓过氧化物酶(myeloperoxidase,MPO)表达的变化,以及小鼠肺组织病理变化和肺血管通透性的改化.结果 ANGPTL4免疫脂质体可以有效增加小鼠肺内ANGPTL4的表达;进而降低ALI小鼠肺泡灌洗液中的TNF-α、IL-6水平和MPO的表达;降低ALI小鼠肺组织湿干比和肺泡灌洗液蛋白浓度,减轻肺组织病变程度.结论 ANGPTL4免疫脂质体能有效减轻LPS诱导的ALI小鼠的肺部炎症损伤反应.
    • 张玉娜; 王国玉; 宋捷; 夏伟
    • 摘要: 目的 探索RNA干扰与131I-免疫脂质体联用在胶质瘤疾病治疗中的潜在价值.方法 在合成pGPU6-GFP-Neo-EGFRvⅢ-shRNA表达载体的基础上,结合核素内放射性131I免疫脂质体,进行细胞实验探索其对胶质瘤细胞U251增殖凋亡的影响.结果 成功构建pGPU6-GFP-Neo-EGFRvⅢ-shRNA载体;同时细胞实验结果显示,shRNA和131I免疫脂质体联用有效抑制胶质瘤细胞U251增殖和促进其凋亡,抑制率达70%.结论 shRNA结合131I免疫脂质体能高效地促凋亡和抑制细胞增殖,为其在胶质瘤治疗中的应用奠定了初步基础.
    • 陈维翠; 刘淑仪; 林爱华; 刘波; 刘岘
    • 摘要: 目的:制备顺磁性抗 HER2免疫脂质体,探讨其对荷人乳腺癌裸鼠模型的 MR 特异成像作用。方法:制备顺磁性抗 HER2免疫脂质体,评价其理化特性及体外细胞结合特性。动物试验选择12只荷人乳腺癌裸鼠,分为2组进行磁共振扫描。实验组为顺磁性抗 HER2免疫脂质体组,对照组为钆布醇组。测量平扫及静脉注射对比剂后第10分钟、1小时、6小时后,肿瘤组织在 T1 WI 的信号强度,计算并比较不同实验组内肿瘤组织的强化率和对比度噪声比。结果:顺磁性抗 HER2免疫脂质体的平均粒径为134.2 nm,多分散系数为0.29,Zeta 电位为-32.49 mV,r1弛豫率为4.67/mM·s;与HER2高表达的 SK-BR-3乳腺癌细胞表现为特异性结合,胞浆出现罗丹明红染。注射顺磁性抗 HER2免疫脂质体后,肿瘤组织表现为显著持久的强化;增强10 min 后肿瘤强化率为121%,1 h 后肿瘤强化率为185%,6 h 后肿瘤强化率为224%。对照组在静脉注射钆布醇10 min 后,肿瘤组织表现为显著强化,强化率为153%,1 h 后的信号强度与平扫相近。两组实验动物在注射对比剂后第1、6 h 后,肿瘤组织的强化率、CNR 差异具有统计学意义。结论:顺磁性抗 HER2免疫脂质体具有长循环时间,高 r1弛豫率,对乳腺癌具有特异性靶向作用。%Objective:To prepare paramagnetic anti-HER2 immunoliposome,and to study its specific character in MR imaging using nude mice bearing human breast cancer model.Methods:Paramagnetic anti-HER2 immunoliposome was pre-pared,its physic-chemical characteristics as well as intracellular distribution were evaluated.Twelve nude mice bearing SK-BR-3 tumor were chosen as experiment animal,which were divided into two groups.Plain and contrast enhanced MR ima-ging were performed.Paramagnetic anti-HER2 immunoliposome was used as contrast agent for the experimental group and Gadobutrol was used for the control group.The signal intensities on T1 WI in plain MRI and at 10min,1h,and 6h after con-trast injection were measured respectively.The enhanced rate and contrast-to-noise ratio (CNR)of tumor in the two groups were calculated and compared.Results:The mean diameter,polydisperisity index,zeta potential and r1 relexivity of paramag-netic anti HER2 immunoliposome were 134.2nm,0.29,-32.49mV and 4.67/mM·s respectively,showing specific binding with high-expressed SK-BR-3 breast cancer cells,rhodamine fluorescence was detected intensively in cytoplasm.After para-magnetic anti-HER2 immunoliposome was injected,marked and long-lasted enhancement in tumor tissue could be assessed, the enhanced rate was 121% after 10min,185% after 1h and 224% after 2h of enhancement.However,in the contrast group,after Gadobutrol as contrast agent was injected,tumor tissue enhanced obviously after 10min,the enhanced rate was 185%,yet the signal intensity decreased 1h after,which was closed to that as plain MRI.The enhanced rate,CNR of tumor 1h and 6h after injection of contrast agent in these two groups showed significant statistic difference.Conclusion:Paramag-netic anti-HER2 immunoliposomes show long circulation time,high r1 relaxivity,could be served as a specific target agent for breast cancer.
    • 王田
    • 摘要: 中药脂质体在我国的研究主要是在单味药方面,主要因为质量标准和制剂工艺较难。所以应从药味少、疗效较好的中药方入手。针对中药提取物成分复杂,提取物量大的特点,应以将中药有效成分或较纯的有效部位制成脂质体着手。口服给药途径为主是中药的重要特点之一,但有关脂质体口服给药后对中药活性成分吸收、分布、代谢、排泄的影响还需要更多的研究。中药脂质体的制备应根据其有效成分的靶点并结合中医理论,与时代结合开发新的剂型。
    • 江峰; 陈江浩; 杨铁虹; 范黎; 乔友备; 吴红
    • 摘要: 目的:制备表面键合曲妥珠单抗(trastuzumab,TMAB)的阿霉素免疫脂质(Doxorubicin-loadedimmunoliposome,DOX-IML),并对其体外性质进行研究.方法:将磷脂酰胆碱、胆固醇、阿霉素、DSPE-MPEG2000以一定比例混合,采用薄膜超声分散法制备阿霉素脂质体,将聚乙二醇衍生物(1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[succinimidyl (polyethylene glycol)-3400]、DSPE-PEG3400-NHS)连接到TMAB;再与阿霉素脂质体连接得到DOX-IML.研究不同浓度的TMAB对DOX-IML入胞能力及细胞毒性的影响;测定免疫脂质体的包封率、载药率、粒径、电荷及稳定性等性质;动态透析法模拟体外释药特性,激光共聚焦观察免疫脂质体对AU565细胞抗体介导的入胞作用;MTT法研究DOX-IML抑制肿瘤细胞的生长.结果:成功制备了表面键合TMAB的阿霉素免疫脂质体,配体载入率分别是53%、75.5%、84%;每毫克DOX-IML中抗体的含量分别是37、83、108 μg·mg-1;阿霉素的包封率为76.85%、载药量为8.03%;粒径131.8nm;表面电荷-27mV.抗体含量83mg·mg-1的DOX-IML组的细胞存活率最低,细胞内荧光强度最高,且该免疫脂质体稳定性良好,具有一定缓释作用.DOX-IML具有较强的特异性靶向作用,其入胞能力和细胞毒性均高于阿霉素脂质体.结论:DOX-IML具有较强的特异性靶向作用,其入胞能力和细胞毒性均高于阿霉素脂质体,抗体含量适中时其入胞能力和细胞毒性最强.
    • 焦得闯; 乔江华; 卢振铎; 黄涛; 崔树德; 刘真真
    • 摘要: Objective To construct the immunoliposomal adriamycin tagged with trastuzumab F (ab') 2 and to investigate its killing effect on human breast cancer cells in vitro.Methods The tastuzmab F(ab')2 and the liposomal adriamycin were linked together by antibody crosslinking method.The morphology of immunoliposomes was observed by transmission electron microscopy (TEM) and their size distribution was measured by graphics software.The immune activity of immunoliposomes was evaluated using the fluorescence microscopy after the fluorescent immunoliposomes or lipoosomes were incubated together with MCF-7 cells.Inhibitory effect of the cell growth at different drug concentrations was measured using methyl thiazol tetrazolium (MTT) 8,16,24 and 32 h after cell culture.The apoptosis was examined by using flow cytometry 32 h after cell culture.Results The immunoliposomal adriamycin tagged with trastuzumab F(ab')2 that was constructed in vitro has an average diameter of 192 nm,and that the diameters under 200 nm accounted for 92.20% of the total.The immunoliposome was superior to liposome at the identification capability to MCF-7 cells,the proportions of the cells which intake drug were (19.39 ±3.33)%,(57.36 ±4.12)%,(89.72 ±-5.88)% and (10.17 ±4.05)%,(25.15 ± 3.77)%,(38.86 ±6.24)% (P<0.05) in two groups respectively after 10,30 and 50 min cell cultrue.The immunoliposome could inhibit the proliferation of MCF-7 cells in a dose (F =1 287.472,P < 0.01) and time (F =2 145.325,P< 0.01)dependent manner; Apoptotic index of MCF-7 cells in immunoliposome group (35.22 ± 3.52) % was obviously higher than that in the control groups (10.31 ± 4.62) % 32 h after transfection.(P < 0.05).Conclusion The immunoliposomal adriamycin tagged with trastuzumab F (ab') 2 was constructed successfully and it can inhibit the proliferation of kill the MCF-7 cells effectively in vitro.%目的 构建Trastuzmab F(ab’)2修饰的阿霉素免疫脂质体并观察其对体外生长的人乳腺癌MCF-7细胞的杀伤作用.方法 抗体交联法制备Trastuzmab F(ab’)2段修饰的阿霉素免疫脂质体;透射电子显微镜观察免疫脂质体的形态及粒径分布;采用荧光标记法测定免疫脂质体活性;噻唑蓝(MTT)法检测MCF-7细胞在不同药物浓度下培养8、16、24、32 h后的增殖差异;流式细胞术检测200 mg/L药物浓度下培养32 h后的各组细胞凋亡.结果 成功构建了Trastuzmab F(ab’)2修饰的阿霉素免疫脂质体;所得免疫脂质体平均粒径为192 nm,粒径小于200 nm者占92.20%;投药10、30、50 min时摄入阿霉素免疫脂质体及阿霉素脂质体的细胞比例分别为(19.39±3.33)%、(57.36 ±4.12)%、(89.72±5.88)%和(10.17±4.05)%、(25.15±3.77)%、(38.86±6.24)%(P<0.05);阿霉素免疫脂质体对MCF-7细胞增殖的抑制作用强于阿霉素脂质体(F=1 256.225,P<0.01),且该抑制作用具有时间(F=2 145.325,P< 0.01)和浓度(F=1 287.472,P<0.01)的依赖性;相同时间内,MCF-7细胞对阿霉素免疫脂质体的摄取要明显高于对照组(P<0.05);TrastuzmabF(ab,)2修饰的阿霉素免疫脂质体对MCF-7细胞增殖具有一定的抑制作用(P<0.01),且该抑制作用具有时间和浓度的依赖性(P<0.01);转染32 h后,阿霉素免疫脂质体组的细胞凋亡率[(35.22±3.52)%]高于对照组[(10.31±4.62)%,P< 0.05].结论 成功构建TrastuzmabF(ab,)2修饰的阿霉素免疫脂质体,其对体外生长的乳腺癌细胞具有较强的杀伤作用.
    • 宋婷; 李伟硕; 黄维; 钱康; 包围; 尹莉芳
    • 摘要: 免疫脂质体作为靶向药物传递体系,以其增效减毒的特性在肿瘤诊断及治疗等领域具有独特的优势,相关研究也得到越来越多的重视.目前,免疫脂质体的制备工艺逐渐完善,选择合适的偶联方案对制剂的活性及稳定性至关重要.了解靶向分子结构及偶联反应机理有助于更好地选择修饰和连接技术,有效实现免疫脂质体靶向传递的作用.本文就免疫脂质体中抗体的类型、抗体和磷脂的修饰技术以及抗体偶联脂质体的方法进行综述.%As a targeted drug delivery system, immunoliposomes improve the therapeutic efficacy of drugs, with reduced the side effect and toxicity. The application of immunoliposomes has its unique advantage in diagnosis and therapy of tumor, related research attracts more and more attentions. A number of methods have been developed for preparing immunoliposomes, and the correct conjugation techniques for coupling antibodies to liposomes are important for the activities and stabilities of immunoliposomes. Knowledge of antibody structure and mechanism of couple reactions provides the foundation for the successful use of the modification and conjugation techniques to ensure the target delivery of immunoliposomes. This review summarizes the classification of antibodies used as target molecules, the modification of antibodies and phospholipids for conjugation and the conjugation strategies for coupling antibodies to liposomes.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号